Current and historical daily PE Ratio for Achilles Therapeutics PLC (
STU:698
) from 2021 to Jun 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Achilles Therapeutics PLC stock (STU:698) PE ratio as of Jun 23 2024 is 0.
More Details
Achilles Therapeutics PLC (STU:698) PE Ratio (TTM) Chart
Achilles Therapeutics PLC (STU:698) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 815
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Achilles Therapeutics PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-24 | At Loss | 2024-04-19 | At Loss |
| 2024-06-21 | At Loss | 2024-04-18 | At Loss |
| 2024-06-20 | At Loss | 2024-04-17 | At Loss |
| 2024-06-19 | At Loss | 2024-04-16 | At Loss |
| 2024-06-18 | At Loss | 2024-04-15 | At Loss |
| 2024-06-17 | At Loss | 2024-04-12 | At Loss |
| 2024-06-14 | At Loss | 2024-04-11 | At Loss |
| 2024-06-13 | At Loss | 2024-04-10 | At Loss |
| 2024-06-12 | At Loss | 2024-04-09 | At Loss |
| 2024-06-11 | At Loss | 2024-04-08 | At Loss |
| 2024-06-10 | At Loss | 2024-04-05 | At Loss |
| 2024-06-07 | At Loss | 2024-04-04 | At Loss |
| 2024-06-06 | At Loss | 2024-04-03 | At Loss |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-03-28 | At Loss |
| 2024-06-03 | At Loss | 2024-03-27 | At Loss |
| 2024-05-31 | At Loss | 2024-03-26 | At Loss |
| 2024-05-30 | At Loss | 2024-03-25 | At Loss |
| 2024-05-29 | At Loss | 2024-03-22 | At Loss |
| 2024-05-28 | At Loss | 2024-03-21 | At Loss |
| 2024-05-27 | At Loss | 2024-03-20 | At Loss |
| 2024-05-24 | At Loss | 2024-03-19 | At Loss |
| 2024-05-23 | At Loss | 2024-03-18 | At Loss |
| 2024-05-22 | At Loss | 2024-03-15 | At Loss |
| 2024-05-21 | At Loss | 2024-03-14 | At Loss |
| 2024-05-20 | At Loss | 2024-03-13 | At Loss |
| 2024-05-17 | At Loss | 2024-03-12 | At Loss |
| 2024-05-16 | At Loss | 2024-03-11 | At Loss |
| 2024-05-15 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
Achilles Therapeutics PLC (STU:698) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Achilles Therapeutics PLC
ISIN : US00449L1026
Share Class Description:
STU:698: ADRDescription
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers